Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro’s SEC disclosures don’t read like a typical med-tech 10-K. Device revenue sits beside milestone payments from 60+ gene-therapy partners, and key risks range from FDA device audits to biologics trial delays. Hunting for the SmartFlow® Cannula sales trend or pinpointing when executives filed a ClearPoint Neuro insider trading Form 4 transactions report can take hours.
Stock Titan solves that problem. Our AI parses every ClearPoint Neuro quarterly earnings report 10-Q filing, highlights segment revenue shifts, and flags cash-burn metrics in plain English. Real-time alerts surface each ClearPoint Neuro Form 4 insider transactions real-time submission, while side-by-side views let you compare last quarter’s MRI-guided neurosurgery unit sales to today’s figures. Whether you’re understanding ClearPoint Neuro SEC documents with AI or need a ClearPoint Neuro annual report 10-K simplified, our summaries translate technical language into actionable data.
Use the platform to:
- Track material agreements via the latest ClearPoint Neuro 8-K material events explained notice
- Analyze R&D spending that fuels next-gen navigation software
- Monitor ClearPoint Neuro proxy statement executive compensation changes alongside ClearPoint Neuro earnings report filing analysis
ClearPoint Neuro reported total revenue of $9.2 million for the quarter, up 17% from $7.9 million a year earlier, led by product revenue of $6.0 million (up 21%). Gross profit was $5.6 million with a 60% margin, slightly below prior-year margins. The company recorded a net loss of $5.8 million for the quarter (basic and diluted loss per share $0.21) and a six-month net loss of $11.9 million (EPS $0.42), driven by higher research and development, sales and marketing, and general and administrative expenses.
Liquidity strengthened to $41.5 million in cash and equivalents at June 30, 2025 after a registered direct equity sale that raised ~$3.3 million net and an initial note issuance that provided approximately $28.7 million net. The company entered a Note Purchase Agreement providing up to $105.0 million of potential notes (initial $30.0 million funded) secured by substantially all assets and carrying PIK interest and future revenue-sharing provisions; management states existing cash is sufficient for at least the next twelve months. Accumulated deficit totaled $203.2 million.
FAQ
What is the current stock price of Clearpoint Neuro (CLPT)?
What is the market cap of Clearpoint Neuro (CLPT)?
